Highlights Unicycive Therapeutics, Inc.

Equities

UNCY

US90466Y1038

Real-time Estimate Cboe BZX Other stock markets 12:58:21 2024-05-16 EDT			5-day change	1st Jan Change
1.045 ^USD	-3.24%		-3.70%	+19.86%

05-15	Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate At the National Kidney Foundation Spring Clinical Meeting	CI
05-13	Unicycive Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate At the National Kidney Foundation Spring Clinical Meeting	05-15	CI
Unicycive Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Unicycive Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate	03-07	CI
Unicycive Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Unicycive Therapeutics Reaches Alignment with the Fda on Path to File New Drug Application for Oxylanthanum Carbonate	23-10-23	CI
Unicycive Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Unicycive Therapeutics' Shares Drop After US FDA Requested Additional Information on Lanthanum Dioxycarbonate Program	23-06-30	MT
Unicycive Therapeutics, Inc. Provides Regulatory Update on Lanthanum Dioxycarbonate Program	23-06-30	CI
Unicycive Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-16	CI
UNICYCIVE THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	23-03-31	AQ
Unicycive Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Unicycive Therapeutics Enters Into License Accord With Lotus Pharmaceutical for Renazorb in South Korea	23-02-02	MT
Unicycive Therapeutics, Inc. Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea	23-02-02	CI
Unicycive Therapeutics Says UK's MHRA Accepts to Start Phase 1 Trial of Drug Candidate to Treat Acute Kidney Injury	22-12-22	MT
Unicycive Therapeutics, Inc. Announces Medicines and Healthcare Products Regulatory Agency in the United Kingdom Complete Review of the Clinical Trial Application and Issue A Notice of Acceptance for UNI-494 First-In-Human Phase 1	22-12-22	CI
Unicycive Therapeutics, Inc. Reports Key Findings of Uni-494 Efficacy in Preclinical Animal Model of Geographic Atrophy	22-11-21	CI
UNICYCIVE THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	22-11-14	AQ
Unicycive Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Unicycive Completes Enrollment of Pivotal Bioequivalence Study for Renazorb™ (Lanthanum Dioxycarbonate), an Investigational Treatment for Hyperphosphatemia in Chronic Kidney Disease Patients on Dialysis	22-11-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Unicycive Therapeutics, Inc.

Equities

UNCY

US90466Y1038

Highlights

Filters